A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropeniaAnne‐Marie Chaftari, Issam Raad, Ray Hachem et al.|Journal of Antimicrobial Chemotherapy|2024Cited by 11